Home » Topics » BioWorld Science

BioWorld Science
RSS

TuA-derived hPep elicits long-term anticancer immunity in mice

Jan. 12, 2022

Discovery of novel hybrid compounds as antitubercular agents

Jan. 12, 2022

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Jan. 12, 2022

CD22 aberrant splicing confers resistance to therapy in B-ALL

Jan. 12, 2022

Mydecine completes model of new serotonin receptor for AI-driven drug discovery program

Jan. 11, 2022

DiNAQOR and CMRI enter research collaboration on cardiac specific AAV capsids

Jan. 11, 2022

Amarna and Redoxis receive grant to support ALPHAVAC project in neurodegenerative diseases

Jan. 11, 2022

BioNTech and Crescendo Biologics partner to develop immunotherapies for cancer and other diseases

Jan. 11, 2022

Targeting aggregated TDP-43 as new strategy for development of ALS and FTLD therapies

Jan. 11, 2022

Acadia and Stroke collaborate on novel RNA-based medicines for neurodevelopmental diseases

Jan. 11, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...